Kelly L. Lancaster
ORCID：0009-0009-4750-199X
发表论文 53 篇 · 总被引 228 次 · h-index 5
代表论文
- Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses (2024 · Nature Communications · 被引 87)
- XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells (2025 · Clinical Cancer Research · 被引 45)
- Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios (2023 · Molecular Cancer Therapeutics · 被引 10)
- Abstract 5810: The impact of scaffold, linker, homogeneity and payload selection on the efficacy and tolerability of anti-tubulin ADCs (2024 · Cancer Research · 被引 2)
- Data from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells (2025 · 被引 1)
- 1053 XMT-2056, a HER2-targeted immunosynthen STING agonist antibody-drug conjugate, induces anti-tumor activity at low doses in preclinical models (2024 · Regular and Young Investigator Award Abstracts · 被引 1)